Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-04-17
2010-08-10
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S321000, C546S187000, C546S198000, C546S202000
Reexamination Certificate
active
07772252
ABSTRACT:
The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D3receptors.
REFERENCES:
patent: 5116970 (1992-05-01), New et al.
patent: 5708018 (1998-01-01), Haadsma-Svensson et al.
patent: 6001834 (1999-12-01), Strupczewski et al.
patent: 2003/0229066 (2003-12-01), Hendrix et al.
patent: 0957102 (1999-11-01), None
patent: WO 00/21950 (2000-04-01), None
A. Bourson et al., Determination of the Role of the 5-ht6 Receptor in the Rat Brain: A Study Using Antisense Oligonucleotides, J. of Pharmacol & Exptal Thera. vol. 374, 1995, pp. 173-274.
A.E. Kelley et al., Opioid modulation of taste hedonics within the ventral striatum, PubMed Abstract 12117573, also cited as Physiol. Behav. 76/3, 365-77 (2002).
A.R. Damasio, Alzheimer's Disease And Related Dementias, Cecil's Textbook of Medicine, vol. 2, 20th Edition, pp. 1992-1996.
A.R. Lingford-Hughes et al., Addiction, PubMed Abstract 12697627, also cited as Br. Med. Bull., 65,209-22(2003).
G. Campiani et al., Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seekin behavior and the role of dopamine D3/D2 receptors., Pub Med Abstract 12930145, also cited as J. Med. Chem. 46/18, 3822-39 (2003).
J.T. Coyle et al., Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation, Science, 1983, pp. 2191184-1190.
R.A. Bressan et al., Is regionally selective D2/D3 dopamine occupancy sufficient to atypical antipsychotic effect? an in vivo quantitative [123I] epidepride SPET study of amisulpride-treated patients, PubMed 12900302, also cited as Am.J. Psychiatry, 160/8, pp. 1413-1420 (2003).
U.S. Appl. No. 07/354,411, filed May 19, 1989, by Strupczewski et al.
Angell Paul
Bordeau Kenneth J
Carey James P
Chiang Yulin
Collar Nicola
Aventis Pharmaceuticals Inc.
Bernhardt Emily
Kurys Barbara E.
LandOfFree
Heterocyclic substituted carbonyl derivatives and their use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic substituted carbonyl derivatives and their use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic substituted carbonyl derivatives and their use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4150587